Preoperative chemoradiation may be more effective for esophageal squamous cell carcinoma compared with adenocarcinoma: results from 15 randomized controlled trials of 2,250 patients

被引:4
|
作者
Ma, Wen-Juan [1 ,2 ]
Zhang, Qiu-Ning [3 ]
Shi, Shu-Zhen [1 ,2 ]
Zhang, Mao-Ying [1 ,2 ]
Zhao, Ye [1 ,2 ]
Tian, Jin-Hui [1 ,2 ]
Wang, Xiao-Hu [3 ]
机构
[1] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou 730000, Gansu, Peoples R China
[2] Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou 730000, Gansu, Peoples R China
[3] Oncol Hosp Gansu Prov, Lanzhou 730000, Gansu, Peoples R China
关键词
Chemoradiation (CRT); esophageal cancer; systematic review; meta-analysis; PHASE-III TRIAL; NEOADJUVANT CHEMORADIOTHERAPY; MULTIMODAL THERAPY; COULD IMPROVE; PLUS SURGERY; CANCER; CHEMOTHERAPY; SURVIVAL; RADIOTHERAPY; METAANALYSIS;
D O I
10.21037/tcr.2018.11.04
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although preoperative chemoradiation (CRT) is considered a standard treatment for patients with esophageal cancer, the results obtained from a variety studies concerning this treatment type still do not completely concur. The purpose of this study is to evaluate the efficacy of preoperative CRT on different histological types in the treatment of esophageal cancer, and to clarify the benefits of preoperative CRT for esophageal cancer. Methods: PubMed, EMBASE, Web of science and Cochrane library were searched for eligible studies published up to December 2017. Three primary out-comes were analyzed. Pooled hazard ratio (HR) and 95% confidence intervals (95% CI) were calculated using a random effects or fixed effects. Heterogeneity of included studies was assessed using the I2 test. Publication bias was examined by the Begg's funnel plot. Results: Fifteen RCTs totaling 2,250 patients were included, compared with surgery alone (SA), the HR (95% CI) for the overall survival (OS) was 0.88 (0.81-0.97), the disease-free survival (DFS) rate was 0.78 (0.64-0.96), and the progression-free survival (PFS) rate was 0.72 (0.56-0.91). To clarify the effect of histological differences on CRT, a subgroup analysis was performed, and the results showed that there was no statistically significant difference in the HR of the OS in squamous cell carcinoma (SCC) and adenocarcinoma (AC) for those treated with preoperative CRT compared with SA [HR of SCC=0.92 (0.83-1.01), P=0.085; HR of AC=0.77 (0.55-1.08), P=0.135]. There was however a statistically significant difference in the HR of the PFS in SCC and AC for those treated with preoperative CRT compared with SA [HR=0.48 (0.32-0.71) for SCC and =0.83 (0.57-1.21) for the AC]. The indirect compare results show there was no statistically significant difference between SCC and AC in OS, ROR (=1.19, 95% CI: 0.84-1.70), but have a statistically significant difference in PFS, ROR (=0.58, 95% CI: 0.33-1.00). Conclusions: Preoperative CRT can improve the OS, PFS and DFS of esophageal cancer. The results of subgroup analyses show that preoperative CRT can improve the PFS of esophageal SCC, but not esophageal AC. However, there was no significant difference in the OS of SCC and AC. And the indirect comparison results confirmed it.
引用
收藏
页码:1421 / +
页数:11
相关论文
共 29 条
  • [21] Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial
    Jiang, Hui
    Makelike, Kanjiebubi
    Chen, Baoqing
    Xi, Mian
    Li, Qiaoqiao
    Hu, Yonghong
    Zhu, Yujia
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [22] Clinical and Biological Prognostic Factors for Locoregional Recurrence in Patients With Thoracic Esophageal Squamous Cell Carcinoma Treated With Radical 2-field Lymph Node Dissection: Results From Long-term Follow-up
    Liu, S.
    Anfossi, S.
    Zheng, Y.
    Cai, M.
    Fu, J.
    Qiu, B.
    Yang, H.
    Liu, Q.
    Fu, J.
    Liu, M.
    Burks, J. K.
    Lin, S. H.
    Reuben, J.
    Liu, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E175 - E175
  • [23] CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial
    Cai Ming-Ci
    Cheng Shu
    Wang Xin
    Hu Jian-Da
    Song Yong-Ping
    Huang Yao-Hui
    Yan Zi-Xun
    Jiang Yu-Jie
    Fang Xiao-Sheng
    Zheng Xiao-Yun
    Dong Li-Hua
    Ji Meng-Meng
    Wang Li
    Xu Peng-Peng
    Zhao Wei-Li
    GENOME MEDICINE, 2020, 12 (01)
  • [24] CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial
    Ming-Ci Cai
    Shu Cheng
    Xin Wang
    Jian-Da Hu
    Yong-Ping Song
    Yao-Hui Huang
    Zi-Xun Yan
    Yu-Jie Jiang
    Xiao-Sheng Fang
    Xiao-Yun Zheng
    Li-Hua Dong
    Meng-Meng Ji
    Li Wang
    Peng-Peng Xu
    Wei-Li Zhao
    Genome Medicine, 12
  • [25] EARLY SIDE-EFFECTS OF INTRA-THORACIC BCG THERAPY IN PATIENTS WITH STAGE-I SQUAMOUS-CELL CARCINOMA, ADENOCARCINOMA, OR LARGE CELL LUNG-CANCER - DATA FROM A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL BY THE LUNG-CANCER STUDY-GROUP
    GAIL, MH
    OLDHAM, RK
    HOLMES, EC
    WRIGHT, PW
    MCGUIRE, WP
    MOUNTAIN, CF
    LUKEMAN, JM
    FELD, R
    HILL, LD
    EAGAN, RT
    PEARSON, FG
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1981, 10 (2-3) : 129 - 137
  • [26] A PLACEBO-CONTROLLED RANDOMIZED DOUBLE-BLIND-STUDY OF ADJUVANT INTRAPLEURAL BCG IN PATIENTS WITH RESECTED T1N0, T1N1, OR T2N0 SQUAMOUS-CELL CARCINOMA, ADENOCARCINOMA, OR LARGE-CELL CARCINOMA OF THE LUNG - LCSG PROTOCOL-771
    GAIL, MH
    CHEST, 1994, 106 (06) : S287 - S292
  • [27] CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial
    Cai, Mingci
    Cheng, Shu
    Xin, Wang
    Hu, Jianda
    Song, Yongping
    Yan, Zixun
    Jiang, Yujie
    Fang, Xiaosheng
    Zheng, Xiaoyun
    Dong, Lihua
    Ji, Mengmeng
    Wang, Li
    Xu, Pengpeng
    Zhao, Weili
    BLOOD, 2019, 134
  • [28] Paclitaxel plus ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase 2 IKF-S627/RAMOS trial of the AIO
    Scheck, Magdalena
    Goetze, Thorsten Oliver
    Ettrich, Thomas Jens
    Schmalenberg, Harald
    Clemens, Michael
    Mahlberg, Rolf
    Heeg, Steffen
    Kanzler, Stephan
    Hapke, Gunnar
    Thuss-Patience, Peter C.
    Kestler, Angelika
    Treschl, Anne
    Frost, Gregg
    Schiemer, Moritz
    Junge, Sabine
    Pauligk, Claudia
    Al-Batran, Salah-Eddin
    Lorenzen, Sylvie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] BGB-A317-LBL-007-202: A phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC)
    Park, Sook Ryun
    Chen, Ming-Huang
    Dechaphunkul, Arunee
    Ding, Ningning
    Lin, Xiao
    Zhang, Jinghui
    Li, Vivian
    Li, Qiao
    Ba, Yi
    CANCER RESEARCH, 2024, 84 (07)